Skip to content
The Peptide TablePeptide Table
Subscribe
Peptide breakdown

BPC-157: The Full Breakdown

The FDA's 2026 review of BPC-157 in plain words: five human studies, animal safety signals, legal status and what is still unknown.

  1. 1By our count, BPC-157 has 0 completed randomized trials; one ran, but its results appear only in a meeting abstract.1,2
  2. 2In rat and dog studies, FDA reviewers flagged clotting and liver warning signs; they found no cancer studies.2
  3. 3The FDA and the EMA have not approved it. Since 28 Oct 2026, HHS says it does not intend to act against licensed pharmacies that compound it under ten conditions.3,4
Read the short answer

The short answer

BPC-157 is a lab-made chain of 15 amino acids, copied from part of a protein found in human stomach juice.2 A team in Zagreb first described it in 1993.2,5 Most research since has been in rodents, and mostly from that team.5 FDA reviewers found five small studies in people.2 The one randomized trial with results, in 53 people with ulcerative colitis, reported them only in a meeting abstract.2

0

completed randomized trials of BPC-157, by our count1

We count a trial only if its results are posted on a registry or published in a journal.

Legal status on 29 Oct 2026
The FDA and the EMA have not approved BPC-157.3 In May 2026, FDA reviewers found no approved product with it "in any country at this time".2 Until 22 April 2026, the FDA listed it in category 2: compounding substances that may present significant safety risks.4,6 Leaving that list did not make it eligible for compounding.4 In July 2026, FDA advisers voted 8 to 6, with one abstention, to let pharmacies make it.7,8 On 28 October 2026, HHS published an interim policy. It says HHS does not intend to take enforcement action against licensed pharmacies and physicians who compound BPC-157 acetate under ten conditions.4 The policy runs until the FDA decides BPC-157 in a final rule.4 In sport, WADA bans it at all times.9
Clinic and pharmacy claims, next to the documents2,5,10
Speeds healing of tendons, ligaments, bones
Rodent studies; a 2026 hamstring trial
Calms gut inflammation, even colitis
53-person trial; FDA called data inadequate
Its "intense healing properties"
Five small, short human studies

Claims as FDA reviewers quoted them from clinic, pharmacy and med spa websites. We name no seller.

The full PDF, free.

  • All five human studies in one table: who took part, how many, the design and how each was reported
  • What the FDA found in rats and dogs, in its own words, and the cancer studies it could not find
  • Legal status in the US, in Europe and in sport, line by line, with the FDA's compounding category
  • The timeline from Zagreb in 1993 to the HHS policy of October 2026, and what is still unknown

A source on every line. No paid placements. No doses.

Instant download. You also get the Wednesday email, which you can leave on the first click. Privacy

The fair line
Five small studies cannot show that BPC-157 works, or that it fails. Our count of 0 is about reporting: the colitis trial ran, but its results are only in a meeting abstract.

This guide was last checked on 28 October 2026. Research and educational information only. Nothing here is medical advice.

  1. [1] The Peptide Table, Method page (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 1)
  2. [2] FDA review of BPC-157 for the compounding advisory committee, 11 May 2026 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 2)
  3. [3] The Peptide Table, BPC-157 record (checked 28 Oct 2026) (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 3)
  4. [4] HHS, enforcement discretion policy on 503A compounding of certain peptides (opens in new tab). Checked 29 Oct 2026Back to text (first mention of source 4)
  5. [5] Mateescu and others, Pharmaceutics (MDPI), 20 May 2026 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 5)
  6. [6] FDA, category 2 list (current as of 22 Apr 2026) (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 6)
  7. [7] McDermott Will & Schulte, client alert, 27 Jul 2026 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 7)
  8. [8] AJMC, 31 Jul 2026 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 8)
  9. [9] WADA, 2026 Prohibited List (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 9)
  10. [10] ClinicalTrials.gov, NCT07437547 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 10)
  11. [11] ClinicalTrials.gov, NCT02637284 (opens in new tab). Checked 28 Oct 2026
  12. [12] Lee and Padgett, Alternative Therapies in Health and Medicine, 2021 (opens in new tab). Checked 28 Oct 2026
  13. [13] Lee, Walker and Ayadi, Alternative Therapies in Health and Medicine, 2024 (opens in new tab). Checked 28 Oct 2026
  14. [14] Reuters, 15 Oct 2026 (opens in new tab). Checked 28 Oct 2026
  15. [15] WADA, 2027 Prohibited List (opens in new tab). Checked 28 Oct 2026
  16. [16] Streamline Feed, 15 Sep 2026, crediting WIRED (opens in new tab). Checked 28 Oct 2026
  17. [17] The Cool Down, 29 Sep 2026, crediting WIRED (opens in new tab). Checked 28 Oct 2026
  18. [18] FDA, advisory committee meeting page, 23 to 24 Jul 2026 (opens in new tab). Checked 28 Oct 2026

More free guides